XuanZhu Bio-B Receives Regulatory Approval for H-Share Full Circulation Plan

Stock News

04/12

XuanZhu Bio-B (02575) has announced that it recently received a formal filing notice from the China Securities Regulatory Commission regarding its application for an H-share full circulation plan. According to the notice, the company has completed the CSRC filing process for the conversion of a total of 357,245,794 non-traded shares held by six shareholders into 357,245,794 H-shares on a one-for-one basis. These 357,245,794 H-shares will be listed and traded on the main board of the Hong Kong Stock Exchange upon completion of the conversion process and after the exchange grants listing approval. The notice remains valid for 12 months starting from the CSRC approval date of March 26, 2026.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1165876354"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1165876354\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1165876354?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-12 18:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165876354","market":"nz","top_or_hot":-1,"title":"XuanZhu Bio-B Receives Regulatory Approval for H-Share Full Circulation Plan","media":"Stock News","content":"<p>XuanZhu Bio-B (02575) has announced that it recently received a formal filing notice from the China Securities Regulatory Commission regarding its application for an H-share full circulation plan. According to the notice, the company has completed the CSRC filing process for the conversion of a total of 357,245,794 non-traded shares held by six shareholders into 357,245,794 H-shares on a one-for-one basis. These 357,245,794 H-shares will be listed and traded on the main board of the Hong Kong Stock Exchange upon completion of the conversion process and after the exchange grants listing approval. The notice remains valid for 12 months starting from the CSRC approval date of March 26, 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XuanZhu Bio-B Receives Regulatory Approval for H-Share Full Circulation Plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXuanZhu Bio-B Receives Regulatory Approval for H-Share Full Circulation Plan\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-04-12 18:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>XuanZhu Bio-B (02575) has announced that it recently received a formal filing notice from the China Securities Regulatory Commission regarding its application for an H-share full circulation plan. According to the notice, the company has completed the CSRC filing process for the conversion of a total of 357,245,794 non-traded shares held by six shareholders into 357,245,794 H-shares on a one-for-one basis. These 357,245,794 H-shares will be listed and traded on the main board of the Hong Kong Stock Exchange upon completion of the conversion process and after the exchange grants listing approval. The notice remains valid for 12 months starting from the CSRC approval date of March 26, 2026.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"製藥","start_time":0,"source_url":"","article_id":"1165876354","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165876354","pubTimestamp":1775988373,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"XuanZhu Bio-B (02575) has announced that it recently received a formal filing notice from the China Securities Regulatory Commission regarding its application for an H-share full circulation plan....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","02575":"轩竹生物-B"},"translate_title":"轩竹生物-B H股全流通方案获监管批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02575":1},"content_text":"XuanZhu Bio-B (02575) has announced that it recently received a formal filing notice from the China Securities Regulatory Commission regarding its application for an H-share full circulation plan. According to the notice, the company has completed the CSRC filing process for the conversion of a total of 357,245,794 non-traded shares held by six shareholders into 357,245,794 H-shares on a one-for-one basis. These 357,245,794 H-shares will be listed and traded on the main board of the Hong Kong Stock Exchange upon completion of the conversion process and after the exchange grants listing approval. The notice remains valid for 12 months starting from the CSRC approval date of March 26, 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}